Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Vandenberghe

Showing results (11-20 of 185) with videos related to

Pageof 19
Sort By:
Blood|August 18, 2012
Ruxolitinib inhibits transforming JAK2 fusion proteins in vitro and induces complete cytogenetic remission in t(8;9)(p22;p24)/PCM1-JAK2-positive chronic eosinophilic leukemiaEls Lierman, Dominik Selleslag, Sanne Smits, et al.
European Heart Journal. Case Reports|March 11, 2022
Combined lenalidomide/bortezomib for multiple myeloma complicated by fulminant myocarditis: a rare case report of widely used chemotherapyMatthias Verbesselt, Evelyne Meekers, Peter Vandenberghe, et al.
Leukemia & Lymphoma|February 5, 2013
Patients with myelodysplastic syndrome and two clones with different interstitial deletions of the long arm of chromosome 5Estelle Verburgh, Anne Hagemeijer, Michel Delforge, et al.
Haematologica|February 19, 2011
The kinase inhibitor TKI258 is active against the novel CUX1-FGFR1 fusion detected in a patient with T-lymphoblastic leukemia/lymphoma and t(7;8)(q22;p11)Bartosz Wasag, Els Lierman, Peter Meeus, et al.
Annals of Hematology|January 20, 2004
Case of megaloblastic anemia caused by intestinal taeniasisPeter Vuylsteke, Celine Bertrand, Gregor E G Verhoef, et al.
Leukemia Research|November 17, 2007
The clinical significance of activated lymphocytes in patients with myelodysplastic syndromes: a single centre study of 131 patientsStef Meers, Peter Vandenberghe, Marc Boogaerts, et al.
Hematology (Amsterdam, Netherlands)|October 31, 2025
Treatment of chronic myeloid leukemia chronic phase patients in third-line setting and beyond: recommendations from a Belgian expert panel in 2025Peter Vandenberghe, Dominiek Mazure, Gaëlle Vertenoeil, et al.
Cancer Genetics|June 29, 2014
A case with a cytogenetically cryptic variant of the inv(16)(p13q22)/t(16;16)(p13;q22)Florence Van Obbergh, Lucienne Michaux, Johan Maertens, et al.
Annals of Hematology|February 9, 2011
CML with e6a2 BCR-ABL1 transcript: an aggressive entity?Karolien Anne Beel, Jan Lemmens, Hilde Vranckx, et al.
Hemasphere|November 15, 2019
FIP1L1-PDGFRα p.T674I-D842L: A Novel and Ponatinib Resistant Compound Mutation in FIP1L1-PDGFRα Positive LeukemiaEls Lierman, Sanne Smits, Niamh Appleby, et al.
Pageof 19

Showing results (11-20 of 185) with videos related to

Sort By:
Pageof 19
Blood|August 18, 2012
Ruxolitinib inhibits transforming JAK2 fusion proteins in vitro and induces complete cytogenetic remission in t(8;9)(p22;p24)/PCM1-JAK2-positive chronic eosinophilic leukemiaEls Lierman, Dominik Selleslag, Sanne Smits, et al.
European Heart Journal. Case Reports|March 11, 2022
Combined lenalidomide/bortezomib for multiple myeloma complicated by fulminant myocarditis: a rare case report of widely used chemotherapyMatthias Verbesselt, Evelyne Meekers, Peter Vandenberghe, et al.
Leukemia & Lymphoma|February 5, 2013
Patients with myelodysplastic syndrome and two clones with different interstitial deletions of the long arm of chromosome 5Estelle Verburgh, Anne Hagemeijer, Michel Delforge, et al.
Haematologica|February 19, 2011
The kinase inhibitor TKI258 is active against the novel CUX1-FGFR1 fusion detected in a patient with T-lymphoblastic leukemia/lymphoma and t(7;8)(q22;p11)Bartosz Wasag, Els Lierman, Peter Meeus, et al.
Annals of Hematology|January 20, 2004
Case of megaloblastic anemia caused by intestinal taeniasisPeter Vuylsteke, Celine Bertrand, Gregor E G Verhoef, et al.
Leukemia Research|November 17, 2007
The clinical significance of activated lymphocytes in patients with myelodysplastic syndromes: a single centre study of 131 patientsStef Meers, Peter Vandenberghe, Marc Boogaerts, et al.
Hematology (Amsterdam, Netherlands)|October 31, 2025
Treatment of chronic myeloid leukemia chronic phase patients in third-line setting and beyond: recommendations from a Belgian expert panel in 2025Peter Vandenberghe, Dominiek Mazure, Gaëlle Vertenoeil, et al.
Cancer Genetics|June 29, 2014
A case with a cytogenetically cryptic variant of the inv(16)(p13q22)/t(16;16)(p13;q22)Florence Van Obbergh, Lucienne Michaux, Johan Maertens, et al.
Annals of Hematology|February 9, 2011
CML with e6a2 BCR-ABL1 transcript: an aggressive entity?Karolien Anne Beel, Jan Lemmens, Hilde Vranckx, et al.
Hemasphere|November 15, 2019
FIP1L1-PDGFRα p.T674I-D842L: A Novel and Ponatinib Resistant Compound Mutation in FIP1L1-PDGFRα Positive LeukemiaEls Lierman, Sanne Smits, Niamh Appleby, et al.
Pageof 19